Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORIC-101 · 2 trials · 1 indication
PK of ORIC-101 as single doses
PK of ORIC-101 as single doses
Safety and tolerability of ORIC-101 as single doses
Safety and tolerability of ORIC-101 as single doses
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | - |
| Regimen B | EXPERIMENTAL | - |
| Regimen C | EXPERIMENTAL | - |
| Regimen D | EXPERIMENTAL | - |
| Regimen F | EXPERIMENTAL | - |
| Regimen H | EXPERIMENTAL | - |
| Regimen I | EXPERIMENTAL | - |
| ORIC-101 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ORIC-101 | DRUG | Capsule or oral suspension |
Inclusion Criteria: * Healthy males or healthy females of non-child bearing potential * Age 18 to 65 years of age * Body mass index of 18.0 to 32.0 kg/m\^2 and weight between 50 kg and 120 kg, inclusive Exclusion Criteria: * Subjects who have received any investigational medicinal product (IMP) i...
ORIC-101 is an investigational small molecule being studied in healthy volunteers. It is in Phase 1 clinical development, with two completed trials in the United States and the United Kingdom. The drug is not approved and remains under investigation.
ORIC-101 is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company traded under the ticker ORIC. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy adult subjects.
ORIC-101 is in Phase 1 clinical development. Two Phase 1 trials in healthy volunteers have been completed, one in the United States and one in the United Kingdom. The drug is investigational and has not been approved.
ORIC-101 has been studied in two completed Phase 1 trials. NCT03324555 enrolled 24 healthy adults in the United States, and NCT03835637 enrolled 32 healthy adults in the United Kingdom. Both trials were controlled and open-label.
ORIC-101 is not FDA approved. It is an investigational small molecule in Phase 1 clinical development, studied only in healthy volunteers. Both of its clinical trials have been completed, but the drug remains unapproved and under investigation.